A phase I study [63], has shown that in healthy volunteers, rheumatoid arthritis and psoriasis patients subcutaneous injections of IL-18BP are well tolerated and within 1–2 weeks show steady levels of the protein in serum. This evidence concerns the gene IL18BP and psoriasis.